BTX Ability to Contract Dermal Fibroblasts Varies by Formulation and Dilution

October 7, 2019

Intradermal botulinum toxin injections can cause dermal fibroblast contraction, providing a lifting effect for facial rejuvenation, but this effect varies based on brand and dilution. In an effort to determine how—and whether—intradermal botulinum toxins create visible lifting in the midface, researchers Rungsima Wanitphakdeedecha MD, MA, MSc, et al, treated normal human dermal fibroblasts with onabotulinumtoxin (ONA), abobotulinumtoxin (ABO), prabotulinumtoxinA (PRABO), incobotulinumtoxinA (INCO), and letibotulinumtoxin A (LETI) in varying dilutions. They then photographed and measured the length of the fibroblasts every two hours from baseline to 12 hours post‐treatment.Read more at MedEsthetics >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Massachusetts Med Spa Owner Pleads Guilty in Federal Counterfeit Injection Case
    • Merz Aesthetics’ Radiesse Receives FDA Approval for Décolleté Wrinkles
    • New Book “Get Found, Get Booked” Reveals a Smarter, Ethical Approach to Marketing for Med Spas and Wellness Practices
    • Bill Regulating Indiana Med Spas Has Passed: What You Need to Know and Why Collective Advocacy Matters
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics